Taliglucerase alfa is a hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease. Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase.
- Mechanism
- Curator reviewed
Taliglucerase alfa is different from human glucocerebrosidase by two amino acids at the N terminal and up to 7 amino acids at the C terminal. This recombinant enzyme allows the hydrolysis reaction of glucocerebroside to glucose and ceramide that naturally occurs in healthy individuals.
- Primary indication
- For the treatment of adult Type 1 Gaucher disease.Curator reviewed · 2 structured indications
- Formula / weight
- C2580H3918N680O727S17 · 56637.9397 Da
- First approval
- Canada, 2014 · United States, 2012
- Also known as
- Glucosylcerebrosidase · prGC-D · prGCD
- Code names
- PRX-112
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which other approved drugs treat the same conditions as Taliglucerase alfa, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account